Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Loma Linda University Cancer Center

Neither a doctor nor a teaching hospital

Research payments

$1,693,173

71 payments

Through program year 2025, Loma Linda University Cancer Center is reported as receiving $1,693,173 in research payments, across 71 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $749,168 10
2024 Research $653,611 3
2023 Research $123,731 5
2022 Research $7,300 17
2021 Research $113,749 16
2020 Research $43,911 13
2019 Research $1,703 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,387,539 10 payments
  2. Merck Sharp & Dohme Corporation $193,675 13 payments
  3. Novartis Pharmaceuticals Corporation $55,196 6 payments
  4. Aurinia Pharma U.S., Inc. $47,222 6 payments
  5. Incyte Corporation $9,085 35 payments
  6. E.R. Squibb & Sons, L.L.C. $456 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) $658,341 2 payments
  2. AMG 510 Ph1b Master Protocol 20190135 $653,141 3 payments
  3. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC $179,629 4 payments
  4. Voclosporin in Adolescents With Lupus Nephritis (VOCAL) $47,222 6 payments
  5. P20180101 AMG 160 plus AMG 160 and AMG 404 6 months fixed dose interval - Child 1_5 $43,488 1 payment
  6. AMG 510 - Adv. KRAS G12C solid tumors_20190135 $31,222 3 payments
  7. A Multicenter Study to Evaluate Safety and Tolerability of Open Label Lcz696 in Pediatric Heart Failure Patients Who Have Successfully Completed the Panorama HF Study A $23,577 2 payments
  8. Multicenter Open Label Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics Oflcz696 Followed By A 52 Week Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Efficacy and Safety of Lcz696 Compared With En $23,278 1 payment
  9. A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma $10,210 4 payments
  10. A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia $7,721 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record